Modulation Of Beta-Catenin Signaling By The Inhibitors Of Map Kinase, Tyrosine Kinase, And Pi3-Kinase Pathways
Wenwen Zhang,Hongyu Zhang,Ning Wang,Chen Zhao,Hongmei Zhang,Fang Deng,Ningning Wu,Yunfeng He,Xian Chen,Junhui Zhang,Sheng Wen,Zhan Liao,Qian Zhang,Zhonglin Zhang,Wei Liu,Zhengjian Yan,Hue H. Luu,Rex C. Haydon,Lan Zhou,Tong-Chuan He
DOI: https://doi.org/10.7150/ijms.6019
2013-01-01
International Journal of Medical Sciences
Abstract:Aberrant activation of beta-catenin signaling plays an important role in human tumorigenesis. However, molecular mechanisms behind the beta-catenin signaling deregulation are mostly unknown because genetic alterations in this pathway only account for a small fraction of tumors. Here, we investigator if other major pathways can regulate beta-catenin signaling activity. By employing a panel of chemical activators and/or inhibitors of several cellular signaling pathways, we assess these modulators' effects on luciferase reporter driven by beta-catenin/TCF4-responsive elements. We find that lithium-stimulated beta-catenin activity is synergistically enhanced by protein kinase C activator PMA. However, beta-catenin-regulated transcriptional (CRT) activity is significantly inhibited by casein kinase II inhibitor DRB, MEK inhibitor PD98059, G-proteins and their receptor uncoupling agent suramin, protein tyrosine kinase inhibitor genistein, and PI-3 kinase inhibitor wortmannin, suggesting that these cellular pathways may participate in regulating beta-catenin signaling. Interestingly, the Ca++/calmodulin kinase II inhibitor HDBA is shown to activate beta-catenin activity at low doses. Furthermore, Wnt3A-stimulated and constitutively activated CRT activities, as well as the intracellular accumulation of beta-catenin protein in human colon cancer cells, are effectively suppressed by PD98059, genistein, and wortmannin. We further demonstrate that EGF can activate TCF4/beta-catenin activity and induce the tyrosine phosphorylation of beta-catenin protein. Thus, our results should provide important insights into the molecular mechanisms underlying Wnt/beta-catenin activation. This knowledge should facilitate our efforts to develop efficacious and novel therapeutics by targeting these pathways.